|
|
|
Neural Tube Defects - NTD |
|
What are these? |
Neural tube defects are defects in the closure of the spinal column or in the development of the brain.
They occur at a very early stage of embryonic development and are a result of the failure of the
neural canal to close properly.
-
When this occurs in the fetus's head, it results in a reduced head size - the head appears very
small and undeveloped.
In this condition, which is called anencephalus and which is always fatal, the brain is only
partially developed.
- When the defect occurs in the spinal column, a condition called spina bifida, the spinal
cord and the spinal nerves protrude.
The degree of severity is determined by the part of the spinal column that is affected and the
number of defective vertebrae, but in most cases this is a functional neurological disorder
involving paralysis of the lower limbs and sometimes urinary and fecal incontinence.
|
What is the frequency of the defect and how is it caused? |
|
|
The frequency of this defect varies according to geographic location, it is
estimated to be about 1:1000 in Israel.
The risk of recurrence in a couple who has already had a pregnancy involving this defect
is 5%, and 10% if there have been two such pregnancies.
The inheritance pattern is multifactorial, meaning both hereditary and environmental
factors are involved.
Some years ago various international research studies found that one of the main
environmental causes of this defect is a maternal deficiency of the vitamin folic acid.
|
|
Can these defects be prevented? |
Giving the mother supplements of folic acid before and during the first weeks of pregnancy
reduces the risk of recurrence by 70% of the original risk.
Hence women who are at risk because they have had a pregnancy with an affected fetus are advised to
take one 5 mg folic acid tablet daily for at least 8 weeks before becoming pregnant,
and for the first 2 - 3 months of pregnancy.
Even women in the general population without a known increased risk are advised to take folic acid,
but a high dosage is not necessary.
Here, 0.4 mg per day is sufficient, and it is best taken with other multivitamins - see
recommendations in "What can be done before pregnancy?"
|
How are these defects diagnosed? |
These defects can be effectively diagnosed in a number of ways:
- Measuring the level of the marker
Alpha-Fetoprotein (AFP)
The level of the marker alpha-fetoprotein (AFP) in the mother's blood is measured as part of the
second trimester biochemical screening test.
It is used in the evaluation of the risk for Down syndrome and congenital defects, and a raised
level is indicative of a neural tube defect.
The test is performed between the 16th and the 18th week of gestation.
In cases where the level is greater than 2.5 multiples of the median for a singleton pregnancy
or 2.0 multiples of the median for a twin pregnancy, an open defect in the nervous system
should be suspected, and possibly other defects also.
In this situation, the family should be offered genetic counseling
in order to discuss what the various possibilities are, and to decide what further investigations
should be undertaken, such as a directed ultrasound scan.
In certain cases, it is advisable to measure the AFP level in the amniotic fluid.
It is important to note that in cases where the opening in the spinal column is covered by skin,
there is no increased secretion of alpha-fetoprotein from the fetus into the amniotic
fluid and the maternal blood, and only a thorough system scan can diagnose this defect.
A thorough ultrasound scan
directed at the spinal column is not performed as a matter of routine in pregnancies without
special problems.
- Ultrasound scan
Anencephalus, which is the most severe type of neural tube defect, can be diagnosed
ultrasonically, usually by the 12th to 14th week of gestation.
If the defect is in the spinal column, the diagnosis is more difficult, but still possible.
In most cases, these defects can be diagnosed during the extended system scan performed between
the 21st and 22nd week.
- Alpha-fetoprotein level in amniotic fluid
Women with a high level of alpha-fetoprotein in the maternal blood are recommended to undergo
amniocentesis (at the expense of the HMO) in order to determine the level of this protein in
the amniotic fluid. If the level is also elevated in the amniotic fluid, the risk of a defect
is relatively high.
This includes neural tube defects in the spinal column or brain, defects of the kidneys or
the closure of the abdominal wall, diseases affecting the integrity of the skin, etc.
In order to differentiate between a defect of the closure of the neural tube and other
conditions, the amniotic fluid is sent for testing for a substance called acetylcholine esterase.
This is secreted into the amniotic fluid only from the neural tube, so its presence
indicates a defect in the closure of the neural tube.
Its absence leaves the other differential diagnoses for elevated alpha-fetoprotein levels.
Ultrasound examination has become more accurate and detailed today, so that it can be used
effectively to detect defects in the spinal column or brain.
It can detect pathological conditions in more than 99% of cases.
This means that in the case of "precious" pregnancies, especially when the maternal blood
alpha-fetoprotein level is not markedly raised (up to 3.00 multiples of the median), or when
there is another reason for the elevated level of AFP, such as placental problems or the
loss of a fetus in a multi-fetal pregnancy, it may be possible to avoid amniocentesis.
This should be discussed with the genetic counselor.
|
|
|